Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Blood

Volumn 100, Issue 9, 2002, Pages 3063-3067

  Richardson, Paul G ^a   Schlossman, Robert L ^a   Weller, Edie ^a   Hideshima, Teru ^a   Mitsiades, Constantine ^a   Davies, Faith ^a   Leblanc, Richard ^a   Catley, Laurence P ^a   Doss, Deborah ^a   Kelly, Kathleen ^a   McKenney, Mary ^b   Mechlowicz, Julie ^b   Freeman, Andrea ^b   Deocampo, Reggie ^b   Rich, Rebecca ^b   Ryoo, Joan J ^b   Chauhan, Dharminder ^a   Balinski, Kathe ^a   Zeldis, Jerome ^a   Anderson, Kenneth C ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Mayer 557 ^*

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; INTERLEUKIN 6; LENALIDOMIDE; M PROTEIN; PARAPROTEIN; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; IMMUNOMODULATION; MALE; MAXIMUM PERMISSIBLE DOSE; MULTIPLE MYELOMA; NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; SOMNOLENCE; STEM CELL TRANSPLANTATION;

EID: 0036839013     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0996     Document Type: Article

References (21)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer Statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
2. Singhal S, Mehta J, Desikan R, et al. Anti-tumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
3. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κ B. Blood. 1996;87:1104-1112.
4. Teoh G, Urashima M, Greenfield EA, et al. The 86 kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells. J Clin Invest. 1997;101:1379-1388.
5. Tai YT. Teoh G, Chauhan D, et al. Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage. J Immunol. 2000;165:6347-6355.
6. Ogata A, Chauhan D, Teoh G, et al. Interleukin-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade. J Immunol. 1997;159:2212-2221.
7. Chauhan D, Pandey P, Hideshima T, et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem. 2000;275:27845-278450.
8. Hideshima T, Nakamura N, Chauhan D, Anderson K. Biologic sequelae of interteukin-6 induced PI3-K/AKT signaling in multiple myeloma. Oncogene. 2001;20:5991-6000.
9. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: Therapeutic applications. Oncogene. 2001;20:4519-4527.
10. Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98:428-435.
11. Podar K, Tai YT, Lin B, et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with Β 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC α activation. J Biol Chem. 2002;277:7875-7881.
12. Urashima M, Chen BP, Chen S, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood. 1997;90:754-765.
13. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943-2950.
14. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia. 2001;15:1950-1961.
15. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.
16. Lentzsch S, LeBlanc R, Podar K, et al. Thalidomide and its immunomodulatory analogs inhibit human multiple myeloma cell growth and angiogenesis in vivo. Leukemia. 2001. In press.
17. Corral LG, Haslett PAJ, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol. 1999;163:380-386.
18. Muller G, Chen R, Huang SY, et al. Amino-substituted thaldidomide analogs: Potent inhibitors of TNF-α production. Bioorg Med Chem Lett. 1999;9:1625-1630.
19. Weber DM, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide with dexamethasone for resistant multiple myeloma [abstract]. Blood. 2000;96:167a.
20. Rajkumar VJ, Hayman SR, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed multiple myeloma [abstract]. Blood. 2001;98:849a.
21. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood. 2002;99:4525-4530.